Biohaven Pharmaceutical Holding Company Ltd.
$2.0M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Calliditas Therapeutics US Inc.
Calliditas Therapeutics US Inc. reported $1,997,506.46 across General Payments, Research, and Ownership to 12,051 physicians and teaching hospitals across 12,052 transactions.
- $2.0M Top quartile payer
- All-tracks total
- 12,052 Top 10% volume
- Transactions
- 12,051 Top 10% reach
- Recipients
- +$717.6K
- General Payments vs PY2023
Calliditas Therapeutics US Inc. reported $1,997,506.46 across all CMS Open Payments tracks (General + Research + Ownership) to 12,051 physicians and teaching hospitals in Program Year 2024 - ranking #448 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,986,661.46, averaging $165.75 per recipient.
How Calliditas Therapeutics US Inc.'s $2.0M all-tracks total breaks down
Calliditas Therapeutics US Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
76/100
Total payments
F
28/100
Transaction volume
A
98/100
Physician reach
A
100/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer calliditas-therapeutics-us-inc Calliditas Therapeutics US Inc.
$2.0M · #448/1,925 · 0.0% industry · PY2024
- TOT $2.0M
- RANK #448
- SHARE 0.0%
- TXN 12,052
- RCP 12,051
- CAT 6
- GEN $2.0M
- ΔGEN +$717.6K
- TOP1 6.2%
- PY 2024
Volume peers
Nearest volume peer: Biohaven Pharmaceutical Holding Company Ltd. ($2.0M)
Calliditas Therapeutics US Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Calliditas Therapeutics US Inc.'s CMS-reported General Payments increased by $717.6K (+56.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CALLIDITAS THERAPEUTICS US INC.PY2023: CALLIDITAS THERAPEUTICS US INC.PY2024: CALLIDITAS THERAPEUTICS US INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,269,069.99
- PY2024
- $1,986,661.46
What the Data Shows for Calliditas Therapeutics US Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Calliditas Therapeutics US Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $878.3K, accounting for 44.2% of this company's General Payments and 389 transactions.
General Payment Breakdown by Type
Calliditas Therapeutics US Inc. made 6 types of general payments. "Honoraria" is the largest category at $878.3K, 44.2% of General Payments.
Calliditas Therapeutics US Inc. reports 6 general-payment categories - the top three are Honoraria (44.2%), Consulting Fee (23.8%), and Food and Beverage (17.8%). The remaining 3 categories make up 14.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Calliditas Therapeutics US Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $878.3K | 389 | 44.2% |
| Consulting Fee | $472.9K | 198 | 23.8% |
| Food and Beverage | $353.3K | 10,966 | 17.8% |
| Travel and Lodging | $280.4K | 492 | 14.1% |
| Space Rental or Facility Fees | $1.5K | 1 | 0.1% |
| Education | $250.00 | 5 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $441,104.43 (22.2%) of $1,986,661.46 in this company's General Payments records across 4,527 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Calliditas Therapeutics US Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Gerald Bernard Appel
$122,899.83 across 94 reported transactions
- 2
Jorge Antonio Larranaga
$106,250.71 across 102 reported transactions
- 3
Sreedhar a Mandayam
$74,332.61 across 97 reported transactions
- 4
Anis a Rauf
$69,181.56 across 80 reported transactions
- 5
Sayna Norouzi
$68,439.72 across 58 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Calliditas Therapeutics US Inc. ranks #448 of 1,925 by total payments (top 23% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,593 of 1,838 by HHI (bottom 13% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Servier Pharmaceuticals LLC : $1.5M total payments, HHI 174
- Mirati Therapeutics, Inc. : $322.0K total payments, HHI 171
- Sekisui Diagnostics, LLC : $21.5K total payments, HHI 171
- Baxter Healthcare : $4.8M total payments, HHI 171
- Fresenius USA Marketing, Inc. : $709.1K total payments, HHI 171
- Alpha Orthopedic Systems : $28.4K total payments, HHI 169
- Calliditas Therapeutics US Inc. (this company) : $2.0M total payments, HHI 169
- National Marrow Donor Program : $4.2M total payments, HHI 169
- Dexcom, Inc. : $2.9M total payments, HHI 168
- Gilead Sciences, Inc. : $39.6M total payments, HHI 168
- Catalyst Pharmaceuticals, Inc. : $1.1M total payments, HHI 167
- Organogenesis Inc. : $2.1M total payments, HHI 167
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Calliditas Therapeutics US Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Calliditas Therapeutics US Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Calliditas Therapeutics US Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Shape Memory Medical Inc.
$2.0M 246 recipients
Compare payment profiles
Roche Diagnostics Corporation
$2.0M 900 recipients
Compare payment profiles
Immunocore Limited
$2.0M 1,028 recipients
Compare payment profiles
Omnia Medical, LLC
$2.0M 110 recipients
Compare payment profiles
Ferring Pharmaceuticals Inc.
$2.0M 21,199 recipients
Compare payment profiles
Put this to use
Calliditas Therapeutics US Inc. ranks #448 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Calliditas Therapeutics US Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Calliditas Therapeutics US Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.